Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib

被引：0
|
作者：
Liam, C. K. [1 ]
Kim, T. M. [2 ,3 ]
Yang, J-J. [4 ,5 ]
Huang, C. [6 ]
Voon, P-J. [7 ]
Tho, L. M. [8 ]
Zhou, Q. [9 ]
Wang, J. [10 ]
Hayashi, H. [11 ]
Tan, D. S. W. [12 ]
Danchaivijitr, P. [13 ]
Nguyen, V. N. [14 ]
Wong, K. H. [15 ]
Yang, J. C-H. [16 ]
Le, X. [17 ]
Ellers-Lenz, B. [18 ]
Karachaliou, N. [19 ]
Ghori, V. [20 ]
Berghoff, K. [20 ]
Wu, Y-L. [5 ,21 ]
机构：
[1] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[2] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[4] Guangdong General Hosp, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Fujian Canc Hosp, Dept Thorac Oncol, Fujian, Peoples R China
[7] Hosp Umum Sarawak, Sarawak, Malaysia
[8] Pantai Hosp Kuala Lumpur, Dept Oncol, Kuala Lumpur, Malaysia
[9] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China
[10] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China
[11] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[12] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[13] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Internal Med,Div Med Oncol, Bangkok, Thailand
[14] Natl Lung Hosp, Hanoi, Vietnam
[15] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[16] Natl Taiwan Univ, Canc Ctr, Dept Med Oncol, Taipei, Taiwan
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[18] Merck Healthcare KGaA, Dept Biostat, Darmstadt, Germany
[19] Merck Healthcare KGaA, Global Clin Dev, Darmstadt, Germany
[20] Merck Healthcare KGaA, Global Patient Safety, Darmstadt, Germany
[21] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
566P
引用
收藏
页码：S1691 / S1691
页数：1
相关论文
共 50 条
  • [41] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [42] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
    Yu, Y.
    Yang, N.
    Zhang, Y.
    Zhang, H.
    Li, M.
    Yu, Q.
    Zhou, J.
    Hu, X.
    Fang, J.
    Zhao, H.
    Feng, J.
    Li, L.
    Shu, Y.
    Wang, X.
    Sun, M.
    Zhang, J.
    Li, M.
    Ren, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [43] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [44] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [45] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [46] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [47] First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis
    Gomez-Randulfe, Igor
    Scanlon, Lauren A.
    Carter, Mathew
    Moliner, Laura
    Cil, Emine
    Califano, Raffaele
    Summers, Yvonne
    Blackhall, Fiona
    Lindsay, Colin R.
    Lewis, Jacob
    Gomes, Fabio
    LUNG CANCER, 2025, 200
  • [48] Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort
    Piotrowska, Zofia
    Chen, Lanyi Nora
    Shum, Elaine
    Park, Cathleen
    Guo, Matthew
    Liu, Ying
    Tran, Misha
    Marks, Jennifer Aline
    Banwait, Mandeep
    Liu, Stephen V.
    Scott, Susan Combs
    Bestvina, Christine M.
    Riess, Jonathan W.
    Marrone, Kristen A.
    Hall, Richard Delmar
    Gentzler, Ryan D.
    Shu, Catherine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [50] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
12345